THOMAS FRANK E

SEC Form 4 insider trading activity

THOMAS FRANK E has filed 3 SEC Form 4 filings (3 transaction rows) across 2 companies, including LRMR, SPRO, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.

On the most recent filing, THOMAS FRANK E is listed as Director at Larimar Therapeutics, Inc. Inside the rolling window, THOMAS FRANK E reported 2 open-market purchases totaling $47K in LRMR and no open-market sales. The largest disclosed transaction in the window is a purchase of 5,000 LRMR shares on Feb 27, 2026, worth $25K.

Companies traded

Other insiders at LRMR

Insider Buying

$47K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

2

in the rolling window

Source
LRMRPurchase$22KNov 12SEC ↗
LRMRPurchase$25KMar 2SEC ↗
Showing 1–2 of 2
1 / 1

Frequently asked questions

How many SEC Form 4 filings has THOMAS FRANK E made?

THOMAS FRANK E has filed 3 SEC Form 4 filings (3 transaction rows) across 2 companies, including LRMR, SPRO since 2026.

Which companies does THOMAS FRANK E trade?

THOMAS FRANK E has filed SEC Form 4 disclosures for 2 companies, including LRMR, SPRO.

When was THOMAS FRANK E's most recent SEC Form 4 filing?

THOMAS FRANK E's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.

What is THOMAS FRANK E's total buy and sell value in the current window?

Inside the rolling retention window, THOMAS FRANK E bought $47K and sold $0 based on SEC Form 4 filings.

What was THOMAS FRANK E's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 5,000 LRMR shares on 2026-02-27, worth $25K, per SEC Form 4 filings.